Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.75)
# 2,095
Out of 5,102 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $26.68 | -25.04% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $21.34 | -29.71% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $13.07 | -38.79% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $24.81 | +101.53% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $154.75 | -12.12% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.94 | +130.55% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $10.33 | +500.19% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.46 | +721.92% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $21.75 | +401.15% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.96 | +308.16% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.42 | +126.24% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $10.68 | +836.33% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $24.13 | -75.13% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $4.96 | +323.39% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $195.24 | -88.22% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $45.78 | -21.36% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $26.68
Upside: -25.04%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $21.34
Upside: -29.71%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $13.07
Upside: -38.79%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $24.81
Upside: +101.53%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $154.75
Upside: -12.12%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.94
Upside: +130.55%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $10.33
Upside: +500.19%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.46
Upside: +721.92%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $21.75
Upside: +401.15%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.96
Upside: +308.16%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.42
Upside: +126.24%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $10.68
Upside: +836.33%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $24.13
Upside: -75.13%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $4.96
Upside: +323.39%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $195.24
Upside: -88.22%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $45.78
Upside: -21.36%